Chromy, David http://orcid.org/0000-0002-1807-8258
Starossek, Lisa
Grabmeier-Pfistershammer, Katharina
Adamek, Sarah
Maischack, Felix
Sammet, Stefanie
Sadoghi, Birgit
Stary, Georg
Willinger, Birgit
Weninger, Wolfgang
Esser, Stefan
Makristathis, Athanasios
Bauer, Wolfgang Michael
Funding for this research was provided by:
Medical University of Vienna
Article History
Received: 10 November 2023
Accepted: 4 April 2024
First Online: 22 April 2024
Declarations
:
: DC served as a speaker and/or advisory board member for Gilead, ViiV Healthcare, and MSD and received travel support from MSD, ViiV Healthcare, and Gilead. LS has nothing to disclose. KGP served as a speaker and/or consultant and/or advisory board member for ViiV Healthcare and Gilead and received travel support from ViiV Healthcare and Gilead. SA has nothing to disclose. FM has nothing to disclose. SS served as advisory board member for MSD and received travel support from Gilead. BS received industry grants/royalties from Abbott/AbbVie, Almirall, Celgene, Eli Lilly, Galderma, Novartis, Pfizer, Trevi Therapeutics, UCB, Janssen Cilag. GS has nothing to disclose. BW served as a speaker for Gilead and advisory board member for MSD. WW served as a speaker, consultant, and/or advisory board member for LEO Pharma, Pfizer, Sanofi Genzyme, Eli Lilly, Novartis, Boehringer Ingelheim, AbbVie, and Janssen. SE served as a speaker and/or advisory board member for Gilead, GSK, Janssen, MSD, ViiV Healthcare, and MSD and received travel support from Gilead, Janssen, MSD, and ViiV Healthcare and research grant from Gilead, Janssen, MSD, and ViiV Healthcare. AM has nothing to disclose. WMB served as a speaker and/or consultant and/or advisory board member for AbbVie, ViiV Healthcare, and Takeda and received travel support from AbbVie, MSD, ViiV Healthcare, and Gilead.